GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: May 12, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on May 12, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share repurchases and does not indicate any new or significant risks.
Key Players & Entities
- GSK plc (company) — The company making the share purchase.
- Citigroup Global Markets Limited (company) — The corporate stockbroker acting on behalf of GSK.
- May 2025 (date) — The reporting period for the transaction.
FAQ
What was the total number of GSK ordinary shares purchased?
The filing states that a 'number' of ordinary shares were purchased but does not specify the exact quantity.
What was the total dollar amount spent on the share repurchases?
The filing does not disclose the total dollar amount spent on the share buyback program.
On what specific dates in May 2025 did these share purchases occur?
The filing indicates the reporting period is for the month of May 2025, but does not list specific purchase dates within that month.
What is the par value of GSK's ordinary shares?
The ordinary shares have a par value of 31 1/4 pence each.
Who is acting as GSK's corporate stockbroker for these transactions?
Citigroup Global Markets Limited is acting as GSK's corporate stockbroker for these share repurchases.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 12, 2025 regarding GSK plc (GLAXF).